Antithrombotic Therapy Following Cardiac Stent Placement

Introduction to Dual Antiplatelet Therapy (DAPT)

The American College of Cardiology recommends dual antiplatelet therapy (DAPT) consisting of aspirin and a P2Y12 inhibitor as the standard first-line antithrombotic regimen following cardiac stent placement, with the specific P2Y12 inhibitor choice and duration determined by clinical presentation and stent type 1, 2

For Acute Coronary Syndrome (ACS) patients, the European Society of Cardiology recommends prasugrel or ticagrelor as the preferred P2Y12 inhibitors, with clopidogrel as an alternative if prasugrel or ticagrelor are contraindicated or unavailable 3
For Stable Coronary Artery Disease (SCAD) patients, the European Society of Cardiology recommends clopidogrel as the standard P2Y12 inhibitor, with prasugrel or ticagrelor considered only in selected high-risk situations 4
The American College of Cardiology recommends DAPT consisting of aspirin (75-325 mg daily) and a P2Y12 inhibitor (typically clopidogrel 75 mg daily) as the standard of care following coronary stent placement 2

For drug-eluting stents (DES), the standard DAPT duration is 12 months 1
For bare metal stents, the minimum DAPT duration is 1 month (preferably up to 12 months) 2
For high bleeding risk patients, a shorter DAPT duration of 3-6 months may be considered 3
For high ischemic risk patients, an extended DAPT duration beyond 12 months may be considered 3

For patients who require oral anticoagulation, a nuanced approach is needed, with triple therapy (oral anticoagulant + aspirin + P2Y12 inhibitor) recommended for the initial period (0-1 month), dual therapy (oral anticoagulant + P2Y12 inhibitor) for the intermediate period (1-6 months), and oral anticoagulant monotherapy for the long-term (>6-12 months) 5, 6, 7
The preferred oral anticoagulant in this setting is a direct oral anticoagulant (DOAC) such as apixaban, which has demonstrated reduced bleeding risk compared to warfarin 6, 7
The American College of Cardiology recommends anticoagulation with apixaban for patients with atrial fibrillation and a CHA₂DS₂-VASc score ≥2 for men or ≥3 for women 7, 5

Proton pump inhibitors should be used in patients at high risk of gastrointestinal bleeding 5, 7
NSAIDs and other medications that increase bleeding risk should be avoided 5
Consider shorter DAPT duration in patients with high bleeding risk 3
Triple therapy increases bleeding risk by 40-50% compared to single or dual therapy 5
A shorter duration of triple therapy should be considered in patients at high bleeding risk 7

Prolonged triple therapy significantly increases bleeding risk without proportional reduction in thrombotic events 6, 7, 5
The optimal antithrombotic regimen balances thrombotic risk reduction against bleeding risk, with the greatest benefit of intensive therapy occurring early after stent placement when thrombotic risk is highest 6, 7
Premature discontinuation of DAPT should be avoided, as it increases the risk of stent thrombosis 2
Both thrombotic and bleeding risks should be reassessed periodically, as the optimal antithrombotic regimen may change over time 7
The American College of Cardiology recommends against using Eliquis for stent patients without a specific indication for anticoagulation, as this increases bleeding risk without additional benefit 7